# Praziquantel Bioequivalence Study

> **NCT03437447** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cisticid
- **DRUG:** Biltricide

## Key facts

- **NCT ID:** NCT03437447
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-18
- **Primary completion:** 2018-07-06
- **Final completion:** 2018-07-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03437447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03437447, "Praziquantel Bioequivalence Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03437447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*